Aviva Ventures, Aviva plc's venture capital arm, has invested in Owlstone Medical Ltd, a medical diagnostics company developing a breathalyser that can detect diseases at a very early stage.
The company is currently developing tests for lung and colorectal cancer, two of the most common terminal cancer conditions worldwide. Aviva Ventures' investment takes Owlstone Medical's total funding to $23.5 million USD (£19.3 million GBP) since its spin out of Owlstone Inc in 2016. Aviva Ventures provides early stage investment to back entrepreneurs with high growth businesses and, over time, expects to have a portfolio of small investments in a number of companies which have significant...
Cura Financial Services are going to be hosting a live broadcast discussing how advisers can benefit from quirky marketing.
Advisers urged to start planning
First Complete's Steve Berry discusses strategies for selling income protection.
With one in five parents taking over 12 months unpaid leave to care for their child during cancer treatment, Aviva's Mark Cracknell believes advisers can help families understand the impact that childhood sickness may have on family finances.